Monday, December 23, 2024 | 01:58 PM ISTEN Hindi

Home / Content / B2B Connect / Pharma / US FDA issues warning letter for Divi's Laboratories' Visakhapatnam unit

US FDA issues warning letter for Divi's Laboratories' Visakhapatnam unit

Last month, US drug regulator had issued an import alert on the products manufactured from this unit

Premium

Divi's Laboratories plant

BS B2B Bureau Hyderabad

Last Updated : Apr 24 2017 | 4:19 PM IST

The Hyderabad-based active pharmaceutical ingredients (APIs) maker Divi's Laboratories has received a warning letter from the US Food & Drug Administration (FDA) for the company's Unit-II at Visakhapatnam.

Earlier, the US FDA had issued an import alert on March 20, 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. However, the US drug regulator had exempted products such as levetiracetam, gabapentin, lamotrigine, capecitabine, naproxen sodium, raltegravir potassium, atovaquone, chloropurine, BOC core succinate and 2,4-wing active ester from the import alert.

“In the Import Alert issued, US-FDA has exempted several products manufactured at the company's Unit-II at Visakhapatnam, Andhra

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in